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Oxidative stressAlmost all eukaryotic mRNAs acquire a poly(A) tail at the 30-end by a concerted RNA processing
event: cleavage and polyadenylation. The canonical PAP, PAPa, was considered the only nuclear
PAP involved in general polyadenylation of mRNAs. A phosphoinositide-modulated nuclear PAP,
Star-PAP, was then reported to regulate a select set of mRNAs in the cell. In addition, several non-
canonical PAPs have been identiﬁed with diverse cellular functions. Further, canonical PAP itself
exists in multiple isoforms thus illustrating the diversity of PAPs. In this review, we compare two
nuclear PAPs, Star-PAP and PAPa with a general overview of PAP diversity in the cell. Emerging evi-
dence suggests distinct niches of target pre-mRNAs for the two PAPs and that modulation of these
PAPs regulates distinct cellular functions.
 2014 The Author. Published by Elsevier B.V. on behalf of the Federation of European Biochemical
Societies. This is an open access article under the CC BY-NC-SA license (http://creativecommons.org/
licenses/by-nc-sa/3.0/).1. Introduction
In eukaryotes, nuclear mRNA synthesis is a multistep process
that begins with transcription and ends with processing at the
30-UTR [1–5]. The various steps of mRNA synthesis – transcription,
splicing, and 30-end formation are functionally interconnected
through a network of synergistic interactions [3,6]. The 30-end pro-
cessing of a precursor mRNA (pre-mRNA) is an essential step in
eukaryotic gene expression, which is comprised of two steps –
cleavage and addition of poly(A) tail [1,4,5,7,8]. Almost all eukary-
otic mRNAs are polyadenylated, a step critical for stability, export
and translation efﬁciency of mRNAs [1,4,5,7,9,10]. Pre-mRNAs are
polyadenylated by enzymes called poly(A) polymerases (PAPs)
which function in a 30-end processing complex comprised of a
large number of protein constituents [11].
The canonical PAP exists in multiple isoforms and at least three
forms of canonical PAP – PAPa, PAPb (PAPT), and PAPc (neoPAP)have been reported [12–18]. Canonical PAPs were considered the
only PAPs that controlled all co-transcriptional polyadenylation
in the nucleus. Apart from PAPa, PAPc also functions in the similar
CPSF and AAUAAA signal dependent polyadenylation of pre-
mRNAs in the nucleus [13]. Another nuclear non-canonical PAP,
Star-PAP [Speckle Targeted PIPKIa Regulated Poly(A) Polymerase]
(RBM21, TUT1), was then reported to polyadenylate certain mRNAs
involved in various cellular processes such as oxidative stress
response and apoptosis [19,20]. Based on similarities in domain
architecture, Star-PAP belongs to a subfamily of non-canonical
PAPs (ncPAPs). So far, seven known ncPAPs have been reported
in humans with diverse cellular functions [21,22].
PAPa and Star-PAP participate in both cleavage and polyade-
nyalation reactions. In addition, Star-PAP exhibits terminal uridylyl
transferase activity toward U6 snRNA [23]. Do the two PAPs com-
pete for target mRNAs? Emerging evidence suggests distinct niches
of target mRNAs for each PAP and there appears to be no cross reg-
ulation of their targets [19,20,24]. Such speciﬁcities in target
poly(A) site recognition could potentially modulate alternative
polyadenylation (APA). This review presents an overview of diverse
PAPs in the cell and compares two functionally similar but distinct
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in properties, mechanism, target mRNA selection, and regulation of
the two PAPs in 30-end pre-mRNA processing.
2. 30-end pre-mRNA processing in gene expression
The 30-UTR of an mRNA is critical for the regulation of gene
expression. During eukaryotic mRNA maturation, the nascent
pre-mRNA undergoes processing at the 30-UTR. This processing at
the 30-end is a two-step event: ﬁrst, the pre-mRNA is endonucleo-
lytically cleaved at the cleavage site, followed by the addition of
poly(A) tail to the upstream fragment of the cleaved RNA, while
the downstream fragment is rapidly degraded [1,4,5,7,8,10]. 30-
end processing is intricately coupled to transcription and splicing,
and also regulates the type, and the amount of mRNA and protein
levels of a particular gene. Thus, mRNA 30-end formation links tran-
scription of a gene with the translation of its mRNA [2,6].
Mass spectrometry analysis identiﬁed 85 protein factors asso-
ciated in the 30-end processing complex [11]. Some of the critical
proteins required for the cleavage and polyadenylation reactions
include subunits of Cleavage and Polyadenylation Stimulatory Fac-
tor (CPSF), Cleavage stimulatory Factor (CstF), Cleavage Factor Im
(CF Im), and Cleavage Factor IIm; Symplekin, PAP, and the nuclear
Poly(A) Binding Protein (PABPN1) (for review [5,25]). Mammalian
CPSF consists of six polypeptides – CPSF 160 (CPSF1), CPSF 100
(CPSF2), CPSF 73 (CPSF3), CPSF 30 (CPSF4), hFip1 andWDR33. CPSF
160 recognises the poly(A) signal, PAS (AAUAAA), a sequence
located approximately 15–30 nucleotide upstream of cleavage site
and interacts with PAP and CstF [26]. Although CPSF 160 binds to
the AAUAAA signal and cooperates with other factors, the assembly
of the stable cleavage complex requires an intact CPSF complex
[26–28]. The CPSF interaction also requires cooperation with CstF
and CF Im for stable association with pre-mRNA [29–32]. Studies
suggest that other trans-acting factors such as splicing factor U1
snRNP interacts with CPSF 160 and promotes its binding to PAS
on the pre-mRNA [33]. In HIV, CPSF 160 can also interact with
sequence element upstream of the poly(A) site other than the clas-
sical AAUAAA signal at the 30-UTR [34,35]. Another subunit of CPSF,
CPSF 73, acts as endonuclease, binds directly to the cleavage site in
a AAUAAA dependent manner and then cleaves the pre-mRNA at
the cleavage site [36,37]. CPSF 30 may cooperate with CPSF 160
in RNA binding [38]. hFip1, one additional CPSF subunit, also binds
PAP and directs PAP to the cleavage site [39]. The exact functions of
CPSF 100 and WDR33 subunits are yet undeﬁned [11,40].
The CstF complex recognises the GU/U rich downstream
sequence element (DSE) and cooperates with CPSF. CstF has three
subunits – 50 (CSTF1), 64 (CSTF2) and 77 (CSTF3) KDa of which
CstF 64 binds the GU/U rich downstream sequence element
(DSE) [30,41,42]. CstF 77 functions as a homodimer and bridges
the 64 and 50 KDa subunits and cooperates with CPSF 160; CstF
50 interacts with the RNA Polymerase II (Pol II) C-terminal domain
(CTD) [26,43,44]. The interaction of CstF and CPSF complexes and
their corresponding associations with DSE and PAS is considered
the most signiﬁcant event in deﬁning the cleavage site. CF Im is a
heterotetramer with two 25 KDa subunits (CPSF5 or NUDT21) that
forms the core of the complex along with two larger polypeptides
of 68 KDa (CPSF6) and/or 59 KDa (CPSF7) subunits. CPSF5 binds
pre-mRNA upstream of PAS to a sequence element that contains
the U(G/A)UA motif. In addition, CF Im cooperates with CPSF for
RNA binding and enhances the recognition of the cleavage site
[31,45–47] CF Im can also direct a sequence-speciﬁc AAUAAA-inde-
pendent polyadenylation by recruiting the CPSF subunit hFip1 and
PAP in vitro [48]. CF IIm consists of two subunits, hPcﬂ 1 and hClp1,
and possibly links CF Im and CPSF within the cleavage complex
[49]. Symplekin is a scaffolding protein that putatively joins a largenumber of proteins together in the complex [50–53]. CPSF, CstF,
Symplekin and CF Im interact with each other stabilising the 30-
end processing complex assembled on pre-mRNA and promotes
recruitment of PAPa. Mammalian PAPa is also required for the
cleavage reaction, however, the mechanism as to how PAPa is
involved in cleavage is not precisely deﬁned [5,25]. After cleavage
of the transcript, PAPa adds a poly(A) tail to the upstream fragment
of cleaved RNA. The nuclear poly(A) binding protein (PABPN1)
binds the nascent poly(A) tail, confers processivity to PAP and con-
trols poly(A) tail length. PABPN1 also interacts with PAPa and CF Im
and enhances the efﬁciency of polyadenylation [54–60]. Thus, a
large number of protein factors cooperate with each other and
assemble at the 30-UTR to accomplish cleavage of the transcript
followed by polyadenylation.
3. Polyadenylation
Polyadenylation is a process of template-independent addition
of a long poly(A) tail to the 30-end of an mRNA. Polyadenylation
activity was ﬁrst identiﬁed some 50 years ago from calf thymus
nuclei extracts [61]. However, it was only a decade later that
poly(A) tails were recognised as a product of post-transcriptional
processing of the mRNA 30-UTR [62–64]. Almost all mammalian
mRNAs have a poly(A) tail at their 30-end, with the exception of
histone mRNA which ends after a highly conserved RNA stem-loop
structure, and lacks a poly(A) tail [65]. The length of a nascent
polyadenylated tail on an mRNA in mammalian cells varies from
200 to 300 adenosine residues [1,9]. In the nucleus, the poly(A)
binding protein, PABPN1 helps to deﬁne the length of the newly
synthesised poly(A) tail during de novo mRNA synthesis
[9,54,56]. PABPN1 interacts with the ﬁrst 11 polyadenosine resi-
dues added, stimulates PAPs afﬁnity for RNA substrate, and in pres-
ence of CPSF induces PAP from its distributive mode to a processive
polyadenylation [54,60,66]. When polyadenylation reaches 250
residues, PAP switches back to its distributive mode resulting
effectively in termination of polyadenylation [58]. The precise
mechanism of this length control is not fully known, it appears
to occur through the formation of a 20 nm spherical structure
involving the poly(A) tail and the bound PABPN1 disrupting the
tripartite, CPSF-PAP-PABPN1 processive polyadenylating complex
[56,67]. Additionally, a role of multi-functional protein nucleo-
phosmin (NPM1) in poly(A) tail length determination has also been
proposed [68,69]. However, a recent poly(A) tail proﬁling indicated
much shorter average lengths of poly(A) tails from various eukary-
otic species (<100 in mammalian cells) [70] likely due to the short-
ening in the cytoplasm [71]. Another genome wide measurement
of poly(A) tail length also demonstrated a median tail length of
50–100 adenosine nucleotides in HeLa and NIH 3T3 cells [72].
The observed length of mammalian poly(A) tails is at least inﬂu-
enced or maybe determined by the shortening reaction in the cyto-
plasm. In addition, there was diversity in the tail length not only
among the transcripts from different individual genes but also
within different mRNA transcripts from the same gene. Intrigu-
ingly, shorter tails were observed for mRNAs encoding ribosomal
or housekeeping proteins [70]. In general, poly(A) tails play crucial
roles in maintaining mRNA stability and turnover, transport of
message from nucleus to cytoplasm, and translation efﬁciency of
mRNA [1,5,9,10]. Moreover, defective polyadenylation has been
linked to various human diseases [73].
3.1. Alternative polyadenylation (APA)
In humans, pre-mRNAs are polyadenylated in several different
ways due to the existence of more than one polyadenylation site,
allowing a single gene to encode multiple mRNA transcripts
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alternatively polyadenylated [76]. APA regulation is an important
event in the gene expression pathway, critical for a number of dis-
eases [73,75,77–79]. Speciﬁc changes in the APA pattern have been
observed during cancer progression, stem cell development, and
tissue speciﬁc expression of genes, yet the mechanism determining
particular APA site(s) remains elusive [78,80–90]. APA changes the
length of the 30-UTR thus affecting the miRNA binding sites, or in
certain cases the coding region in the mRNA resulting in proteins
with different domains [78,81,84,91,92]. Therefore, APA potentially
alters the dynamics and properties of a transcript affecting stabil-
ity, translation and/or subcellular localisation.
4. Poly(A) polymerase (PAP)
PAPs are the enzymes involved in the polymerisation of adeno-
sine residues to form long poly(A) tails at the 30-end of eukaryotic
mRNAs. PAPs are involved not only in the polyadenylation reaction
but also in the CPSF mediated cleavage reaction [1]. The gene struc-
ture of PAP indicated possible different PAP isoforms by alternative
RNA processing [93]. Consistently, different PAP isoforms have
been isolated from various sources [18,94–96].
4.1. Canonical PAP (PAPa) – the nuclear enzyme
Canonical PAPa belongs to a nucleotidyl transferase superfam-
ily of DNA Polymerase b [97,98], and is responsible for the polyad-
enylation of nascent mRNAs in the nucleus. PAPa has three distinct
domains: a catalytic domain at the N-terminus, an RNA binding
region, and two C-terminal nuclear localisation signals (NLS1 and
NLS2) followed by a 20 KDa extended region enriched in serine
(S) and threonine (T) residues [99–102]. Crystal structure of mam-
malian PAPa showed an aspartate triad in the active site similar to
the DNA pol b coordinating the metal ions required for catalysis
and ATP recognition [99,101,103,104]. Interestingly, the C-terminal
S/T enriched region is highly phosphorylated [99,100,102,105,106].
Moreover, there are seven cyclin dependent phosphorylation sites
in this region [106–108]. Phosphorylation at these sites represses
the PAP activity. Phosphorylation of PAP will be discussed in a later
section. In addition, interaction sites for U1A and U2AF65 splicing
factors are present at the C-terminus [109–111] indicating the
regulatory potential of the C-terminal end.
4.2. Multiple isoforms of canonical PAP
In humans, three genes encode the canonical PAP – PAPOLA
(PAPa), PAPOLB (PAPb or T) and PAPOLG (PAPc or neoPAP). While
PAPa is ubiquitously expressed, PAPb is testis-speciﬁc and regu-
lates transcripts expressed during spermatogenesis [12,14,15].
Both PAPT and PAPc share similar structural motifs and sequence
identity with PAPa, except for the divergent C-termini. These dif-
ferent forms of PAP (PAPa, b, or c) are believed to have arisen from
a common PAP by gene duplication [12,13,15]. PAPc appears to
have the same function in cleavage and polyadenylation as that
of PAPa. Interestingly, PAPc exhibits monoadenylation activity
towards small RNAs in addition to its normal PAP activity [112].
Furthermore, PAPc was found to be speciﬁcally active during
tumourigenesis, thus suggesting functional diversity [13,17]. Apart
from these different forms of PAP, there exists other PAP related
genes in humans. At least two such PAP related gene sequences
have been identiﬁed from the in silico searches in the human gen-
ome [113].
There are at least six isoforms of canonical PAPa generated by
alternative splicing, PAP I–VI [16,18,96]. PAPs I, II and IV are longer
versions with the full length catalytic domain while III, V and VI are
truncated PAPs lacking parts of the catalytic domain. PAPs I, II andIV are functionally active, and are generated by alternative splicing
of the last three exons [16,18]. PAP II is the predominant PAP
isoform in most cell types [16,94,114]. Truncated PAPs, PAPs III,
V and VI lack NLSs, the extended C-terminus in addition to parts
of the catalytic domain. These PAPs are generated by alternative
polyadenylation and/or splicing events, and do not encode func-
tional proteins in vivo [18,100,115]. Two additional longer PAP
isoforms (PAP VIII and IX) generated by alternative splicing of
exons 20, 21 and 22 have also been reported [116]. However, at
this time the signiﬁcance of divergent C-termini of the full length
PAPs is unclear. Interestingly, the C-terminal S/T rich region
which is present in all longer PAP isoforms is dispensable for its
activity in vitro [16,102]. Therefore, it is likely to act as a regulatory
domain, and it could have a selective advantage of differential
interaction with other distinct trans-acting cleavage factors or
regulators resulting in functional diversity. Moreover, studies have
shown distinct cellular functions for different PAP isoforms in
plants [117]. Schematics of various human PAP isoforms have been
depicted in Fig. 1.
4.3. Non-canonical PAP (ncPAP) – PAPs with functional diversity
ncPAPs are PAP-related members of the Pol b superfamily
involved in diverse cellular functions as detailed below. Unlike
the canonical counterparts, which add long poly(A) tail during
mRNA maturation, ncPAPs typically add short terminal tails and
target a variety of substrates (snRNA, miRNA, aberrant rRNA,
snoRNA, histone mRNA, etc.). Surprisingly, there are reports of
polyadenylation of select pre-mRNAs by one of the ncPAP, Star-
PAP (discussed in detail in the following sections) [19,20]. This is
an unusual function for an ncPAP as most ncPAPs add short tails.
In addition, ncPAPs have distinct domain architecture. For exam-
ple, all ncPAPs contain a conserved (among ncPAPs) PAP associated
domain immediately following the catalytic (PAP) domain (Fig. 1).
There are at least seven potential ncPAPs in humans (PAPD1,
PAPD4, PAPD5, POLS, RBM21, ZCCHC6, ZCCHC11). PAPD1 (hmtPAP)
is a mitochondrial PAP that polyadenylates mitochondrial mRNA
[118]. PAPD1 mediated polyadenylation can generate UAA stop
codon in some mitochondrial mRNAs, which is not encoded by
the mitochondrial DNA [119–121]. However, the functional signif-
icance of mitochondrial polyadenylation is still a topic of debate
[118,121,122]. PAPD1 was also reported to uridylate histone mRNA
along with PAPD5 to target it for degradation [123] although the
actual PAP that uridylates histone mRNA is somewhat controver-
sial [124]. hGLD2 (PAPD4) is a cytoplasmic PAP that polyadenylates
short (A)-tailed mRNAs in the cytoplasm [125,126] and is involved
in diverse functions such as embryonic development, cell cycle,
germline maturation, synaptic plasticity, learning and memory
[126–131]. hGLD2 also polyadenylates p53 mRNA in the cytoplasm
[128,132]. hGLD2 targets mRNAs containing a cytoplasmic polyad-
enylation element (CPE) at the 30-UTR that is recognised by the
regulatory protein CPEB (CPE binding protein). Phosphorylated
CPEB interacts with CPSF 160 and helps recruit the CPSF complex
(CPSF 160, 100 and 30) to the PAS. This complex is then stabilised
by another processing factor, symplekin. This processing complex
then recruits the cytoplasmic PAP, hGLD2 at the 30-end to elongate
the poly(A) tail [129,133,134]. Unlike the nuclear polyadenylation
complex, the CPSF 73 subunit is not present in the cytoplasmic
polyadenylation complex [135].
PAPD5 and POLS (PAPD7) are two human orthologues of yeast
Trf4 involved in nuclear surveillance of a wide range of nuclear tar-
get RNAs [136–139]. Both PAPs also polyadenylate aberrant rRNA
precursors to target them for degradation [139,140]. PAPD5 has
also been implicated in the processing of small nucleolar RNAs
(snoRNAs). PAPD5 oligoadenylates late intermediates of H/ACA
box snoRNAs during 30-end shortening, which are then trimmed
Fig. 1. Schematic representation of the domain architecture of human PAPs. Canonicals – PAPa, three functional splice isoforms, PAPb (PAPT), PAPc (neoPAP); and non-
canonicals – Star-PAP, hGLD2 (PAPD4), hmtPAP (PAPD1), ZCCHCH11 are shown. All canonical PAPs including the splice isoforms have similar structural organisation (except
divergence at the C-terminus), comprising a catalytic domain (PAP domain) – red, an RNA binding domain – blue, nuclear localisation signals – green, and a C-terminal Ser/
Thr rich regulatory region – brown. Non-canonical PAPs have diverse organisation comprised of a catalytic domain (PAP or PUP) – red, a PAP associated domain – yellow, RNA
recognition motifs (such as ZF – orange, Lucine Zipper – magenta, an RNA binding domain – blue, RNA recognition motif – light blue), and Nuclear localisation signals – green.
In addition, Star-PAP PAP domain is split by a proline rich region (pink). The size of each protein is indicated (not to scale).
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Another ncPAP, Star-PAP (RBM21), controls 30-end processing of
mRNAs involved in oxidative stress response [20]. Star-PAP also
shows uridylation activity toward U6 snRNA substrate [23]
(discussed in detail in subsequent sections). ZCCHC11 (TUT4) and
ZCCHC6 (TUT7) are orthologues of yeast Cid1 uridyl transferase
with extensive homology to each other and regulate diverse
RNA species [21,124,142–145]. ZCCHC11 and ZCCHC6 uridylate
miRNA let-7 precursor through interaction with Lin 28, thus con-
trolling let-7 biogenesis [144,146–148]. Further, ZCCHC11 medi-
ated uridylation controls microRNA, miR-26 activity [145]. and
has also been implicated in histone mRNA degradation [124]. Thus,
the existence of various canonical and non-canonical PAPs suggests
diverse functional signiﬁcance of PAPs in the cell. A list of various
human canonical and non-canonical PAPs can be found in Table 1.
4.4. Star-PAP – a schizophrenic polymerase
Star-PAP (Speckle Targeted PIPKIa Regulated Poly(A) Polymer-
ase) is a nuclear ncPAP regulated by lipid messenger phosphatidyl
inositol 4,5 bisphosphate (PI4,5P2) [20,149–151]. Star-PAP was
identiﬁed as an interacting partner of phosphatidyl inositol
phosphate kinase Ia (PIPKIa) [20]. Star-PAP contains a PAP domain
split by a proline rich region (PRR) of 200 amino acids that isphosphorylated by casein kinase I (CKI) isoforms a and e
[152,153]. Star-PAP has two polynucleotide binding domains – a
zinc ﬁnger (ZF) and an RNA recognition motif (RRM), both required
for Star-PAP RNA binding [24]. Star-PAP and PAPa have similar
function but with a distinct mechanism regulating a select set of
mRNAs [20,24]. Star-PAP along with PIPKIa speciﬁcally control
genes involved in the oxidative stress response such as heme oxy-
genase-1 (HO-1) and NAD(P)H:Quinone Oxidoreductase (NQO-1)
[20,152] and the pro-apoptotic gene Bcl-2 interacting killer (BIK)
[19].
Star-PAP was initially identiﬁed as U6 terminal uridylyl trans-
ferase (TUTase), which uridylates U6 snRNA [23] involved in cellu-
lar splicing [23,154]. Concomitantly, siRNA knockdown of Star-PAP
was reported to dramatically reduce cell viability. However, the
exact reason for loss in cell viability is unclear. Given Star-PAP’s
apparent role in 30-terminal modiﬁcation of U6 snRNA, it is tempt-
ing to think of a global impact of Star-PAP on splicing efﬁciency.
However, at present, there is no direct evidence to suggest any role
for Star-PAP or a U6-TUTase-catalysed reaction in cellular splicing
[23,155,156]. Alternatively, Star-PAP as a PAP is involved in various
cellular processes including stress response and apoptosis. Micro-
array data indicated that a number of Star-PAP targets are genes
critical for cell survival [19,20]; thus, loss of Star-PAP could result
in cell death. Surprisingly, the study that identiﬁed Star-PAP as a
Table 1
List of various human canonical and non-canonical PAPs.
Name of the PAP Localisation Functional signiﬁcance Reference
Canonical PAP
PAPa
PAP I
PAP II
PAP III
PAP IV
PAP V
PAP VI
Nuclear PAP II is the most predominant PAP; involves in general 30-end
processing of all nuclear nascent pre-mRNAs
(PAP I and IV – function not clear, likely similar to PAP II)
PAP V, III, VI are truncated inactive form, Do not encode functional
proteins
[16,18,94,102,114]
PAP b (PAPT) Nuclear/Cytoplasmic Testes speciﬁc – spermatogenesis [12,15]
PAP c/neoPAP Nuclear Tumourigenesis, monoadenylation activity towards small RNA [13,17,112]
Non-canonical PAP
PAPD1 (hmtPAP) Mitochondrial Mitochondrial mRNA stabilisation, histone mRNA degradation, stop
codon regeneration
[118,120–123]
PAPD4 (hGld2) Nuclear/cytoplasmic Cytoplasmic mRNA polyadenylation, miRNA stabilisation [122,125,126,128]
For review [127,129]
PAPD5 Nuclear Aberrant rRNA degradation, histone degradation, processing of
snoRNAs, various other RNA targets
[21,139–141]
POLS (PAPD7) Nuclear Not clearly deﬁned, likely redundant to PAPD5 [21,140]
ZCCHC6 (TUT 4) Nuclear Similar to ZCCHC11; regulate Let 7 biogenesis [147,157]
ZCCHC11 (TUT 6) Nuclear miRNA regulation (let7, mi26a and others), histone mRNA degradation [124,143,147,157]
Star-PAP (RBM 21, TUT1) Nuclear Oxidative stress response, DNA damage induced apoptosis and various
other cellular functions
[19,20,23,24]
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down on the cell viability [20]. In addition, the yeast counterpart
Cid11 is not required for cell viability [22]. Nevertheless, Star-
PAP uridylation activity has been conﬁrmed in vitro [20,23].
Is Star-PAP a PAP or a TUTase or both in vivo? Although Star-
PAP has both PAP and TUTase activities, at the physiological con-
centration of ATP adenylation activity competes over uridylation
suggesting a possible predominance of polyadenylation function
in the cell [20]. Nonetheless, with a clear in vitro TUTase activity
of Star-PAP, one can envisage a distinct physiological role of Star-
PAP uridylation function in the cell. In fact, many ncPAPs have both
uridylation and adenylation functions [118,121–123,140]. There-
fore, it is conceivable that Star-PAP has a complex role, for exam-
ple, while polyadenylation regulates a select set of mRNAs,
uridylation regulates U6 or other target RNAs. Another possibility
is that both activities combined result in a heterogeneous 30-end
tail with both A’s and U’s. A related example has been reported
in ﬁssion yeast where few Us were incorporated at the end of the
30-poly(A) tail [157,158]. This modiﬁcation has been implicated
in a new pathway of 50–30 mRNA degradation in ﬁssion yeast,
where addition of short terminal Us at the end of polyadenylated
mRNAs appears to stimulate decapping and initiates the mRNA
degradation pathway [158]. Widespread uridylation has also been
reported downstream of the mammalian mRNA poly(A) tail [72].
Furthermore, Dis3L2, a new 30–50 exonuclease, involved degrada-
tion of oligouridylated RNAs, was recently identiﬁed in multiple
eukaryotes [159–161]. Dis3L2 functions independent of the exo-
some, and uridylation of its targets acts as an RNA decay signal
for Dis3L2. Moreover, addition of >10 uridines to the 30-end of its
miRNA target stimulates Dis3L2’s enzymatic activity in vitro
[159–161]. These studies also suggest a possible general role of
terminal uridylation as signal for RNA decay in eukaryotes. Thus,
presence of U’s in the poly(A) tail will have a profound impact on
the functional dynamics of an mRNA. Unfortunately, no sequence
information of Star-PAP target poly(A) tails is available so far,
and hence worthwhile exploring. Such properties, as mentioned
above, would make Star-PAP schizophrenic in nature, or a truly
non-canonical enzyme.5. Mechanism of 30-end RNA processing – Star-PAP versus
canonical PAP
Cis-elements present at the 30-UTR play an important role in
speciﬁc cleavage and polyadenylation of pre-mRNAs. There are at
least four consensus cis-elements at the canonical 30-UTR [7]. The
ﬁrst important motif is a conserved hexamer AAUAAA (PAS), which
determines the position of the cleavage site. Mutation in this con-
sensus hexamer affects the efﬁciency of 30-end processing
[162,163]. Point mutations in the AAUAAA signal have often been
linked to human diseases. For example, two point mutations in
the AAUAAA hexamer have been characterised in patients suffering
from thalassaemia (AAUAAG in the a2-globin and AACAAA in the
b-globin) [164,165]. An A-G point mutation (AAUAAA – AAUGAA)
in FOXP3 gene results in a rare X-linked autoimmune disorder,
IPEX (immunodysregulation polyendocrinopathy enteropathy
X-linked syndrome) [166]. However, variation in the second nucle-
otide in the consensus hexamer to U (AUUAAA) is the most widely
occurring PAS after AAUAAA (for reviews [1,167]). Studies on
human and mouse ESTs have indicated AAUAAA (70%) as the most
common hexamer followed by AUUAAA (15–20%) among all PAS
containing ESTs [76,168]. Analysis of human UTRs and ESTs has
indicated alternate signals as well. AGUAAA, UAUAAA, CAUAAA,
GAUAAA, AAUAUA, AAUACA, AUAGA, and ACUAAA are few other
widely occurring hexamers [168,169]. However, such variants
(including the common AUUAAA hexamer) are less efﬁciently
processed than the classical AAUAAA [168]. The second important
cis-element at the 30-UTR is the cleavage site situated 15–30
bases downstream of PAS. This position of the cleavage site is
determined by the locations of both PAS and DSE [30,170].
Although the sequence at the cleavage site is not very conserved,
in vertebrates the majority of the cleavage sites are located imme-
diate downstream of an adenosine residue (with preference for A
over G), the most optimal site being CA [25,163]. In fact, in the
human prothrombin gene, the position of the cleavage site is
mutated from weaker CG to most optimum CA, inducing the
expression, to cause a mild thrombophilia phenotype [171–173].
The third element is a GU/U-rich DSE located 20–40 bases
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of the cleavage site. It is less conserved than the PAS and has either
a GU-rich (YGUGUUYY, where Y = pyrimidine) or a U-rich
(UUUUU) element [174–177]. And, ﬁnally the last cis-element is
a U-rich, upstream sequence element (USE) situated 1–20 nucle-
otides upstream of PAS [7]. USEs can inﬂuence the efﬁciency of PAS
and/or complement for the suboptimal PAS or DSE [35,178–181].
In addition, there are auxilary upstream and downstream sequence
elements. While the auxiliary upstream sequence mostly contains
either U rich (UUUU) or UAUA/UGUA, the auxiliary downstream
sequences are generally G-rich [182–185] (for review [5,25]). They
are less conserved in position as well as sequence than the four
core elements.
Except for the intact AAUAAA signal, Star-PAP target messages
harbour other cis-elements at the 30-UTR that are distinct from that
of canonical 30-UTR [19]. Star-PAP targets have suboptimal DSEs,
with U/GU deplete sequence, which potentially renders CstF
dispensable for Star-PAP mediated 30-end processing. In addition,
there is no noticeable canonical motif like USE; instead, a 40–
60 nucleotides long GC-rich sequence of Star-PAP binding region
upstream of the PAS is present [19,24]. These variations in the
cis-regulatory elements of Star-PAP and canonical PAP target
30-UTRs explain the mechanistic differences of the two PAPs. A
comparison of the 30-UTR cis-elements of canonical and Star-PAP
regulated genes is depicted in Fig. 2.
Recent advances in the understanding of 30-end processing have
indicated distinct mechanisms for different PAPs. While PAPa is
mechanistically well explored, studies on Star-PAP are still emerg-
ing. The two PAPs share similar cleavage factors but assemble dis-
tinct 30-processing complexes and control speciﬁc sets of target
mRNAs in the cell. Around 85 proteins are associated with the
canonical 30-end processing complex. Emerging evidence suggests
that Star-PAP may not require all canonical cleavage factors, while
requiring additional proteins not present in the canonical 30-end
processing machinery. In the canonical mechanism, CPSF 160
binds the PAS, cooperates with CstF and CF Im. CPSF 160 then
recruits PAPa through direct interaction at the cleavage site
[26,28,29,45]. PAPa has low afﬁnity for RNA substrate and lacks
RNA binding speciﬁcity [100,114]; and no precise role of PAPa in
the cleavage reaction has been deﬁned. In contrast, Star-PAP
directly binds pre-mRNA and plays a structural role to assemble
the cleavage complex. Star-PAP directly interacts with CPSF 160
and 73 [19,24]. Star-PAP binding to the pre-mRNA and CPSF 160
recruits CPSF 160 to the PAS. CPSF 73 is then recruited to the
cleavage site by its interaction with CPSF 160 and Star-PAP [24].
The mechanism of canonical PAP and Star-PAP mediated 30-end
processing is shown in Fig. 3.
Star-PAP has two RNA binding motifs: a Zinc Finger (ZF) and an
RNA recognition motif (RRM), both required for mRNA bindingFig. 2. 30-UTR consensus cis-elements of canonical and Star-PAP target 30-UTRs. The can
cleavage site 15–30 nucleotide downstream of PAS, G/GU rich DSE and a U-rich USE (fo
(AAUAAA), they have suboptimal DSEs (deplete U sequence), and no regular USE prese
upstream of the cleavage site is present.[24]. This implies a complex binding motif of Star-PAP on its target
RNA with multiple nucleotide elements that in combination inter-
act with ZF, RRM, or both. This is consistent with the large Star-PAP
footprint observed on targets, HO-1 and BIK UTR RNA [19,24]. The
multiple binding elements could in turn enhance both speciﬁcity
and ﬂexibility for targeting speciﬁc pre-mRNAs. Moreover, Star-
PAP and CPSF subunits 160 and 73 reconstitute cleavage of HO-1
UTR RNA in vitro. The resulting 30-cleavage is speciﬁc but weak,
suggesting that optimum in vivo cleavage requires other process-
ing factors [24]. In contrast, no combinations of recombinant cleav-
age factors from the canonical mechanism could reconstitute
in vitro cleavage reaction. This demonstrates that Star-PAP medi-
ated 30-end processing requires different sets of cleavage factors.
In addition, due to low U/GU DSE on Star-PAP target mRNAs CstF
which otherwise cooperates with CPSF-RNA binding in the canon-
ical mechanism is likely dispensable in the Star-PAP mediated
30-end processing mechanism [19]. Alternatively, different combi-
nations of cleavage factors might function with speciﬁc PAPs
(Star-PAP and PAPa) to regulate distinct target messages.
6. Implications of PAP diversity – Star-PAP vs canonical PAP
While the diversity of cellular PAPs is well known, the signiﬁ-
cance of PAP multiplicity is not clear. Multiple lines of evidence
suggest the involvement of different PAPs in distinct cellular func-
tions as illustrated by the functional speciﬁcities of various canon-
ical isoforms and non-canonical PAPs. For example, ncPAPs such as
hGLD2 or PAPD1 have speciﬁc roles in regulating cytoplasmic or
mitochondrial mRNAs [118,121,126,135] while canonical PAPs
such as PAPb and PAPc speciﬁcally regulate mRNAs during sper-
matogenesis and tumourigenesis respectively [12,15,17]. More-
over, longer canonical PAPa isoforms, I and IV exhibit tissue
dependent expression [18]. On the other hand, Star-PAP regulates
speciﬁc mRNA targets in the nucleus, which are otherwise inacces-
sible to PAPa [20,24]. Therefore, the regulation of distinct PAPs
might differentially control expression of speciﬁc mRNAs.
6.1. Multiple types of 30-end tail formation
There are two basic types of 30-end tails reported so far: poly(A)
tail and short terminal (U)-tail, both of which can have either
destabilising or stabilising functions on RNA target. For example,
poly(A) tails on mRNAs primarily confer stability to the transcript,
while polyadenylation of aberrant tRNAs targets them for degrada-
tion [139,140]. Such destabilising function of poly(A) tail is well
established in prokaryotic polyadenylation [186,187]. In general,
polyadenosine tail present on mRNA 30-ends can be either long
poly(A) tail with stabilising function as in regular mRNA formation,
or shorter (A) tail that destabilises RNA for degradation [9].onical 30-UTR has distinct consensus elements such as the AAUAAA poly(A) signal,
r a review see Ref. [7]). In case of Star-PAP target mRNAs, except for the intact PAS
nt; instead, a GC-rich Star-PAP binding region is found around 40–50 nucleotides
Fig. 3. A comparative model of the assembly of canonical and Star-PAP mediated 30-end processing complexes. In the canonical model, CPSF 160 recognises the PAS and
cooperates with CstF and CF Im and other factors to assemble a stable cleavage complex. The CPSF complex then recruits PAPa to the cleavage site by virtue of CPSF 160 direct
interaction to PAPa (for a review see Refs. [1,4,5,7,8]). hFIP 1 also interacts with PAP to help position PAPa to the cleavage site. In case of Star-PAP mediated 30-end processing,
Star-PAP directly binds the target pre-mRNA UTR, a GC-rich sequence upstream of poly(A) signal, and helps recruit CPSF 160 and 73 subunits to the cleavage site to assemble a
stable cleavage complex (see Refs. [20–22]). This complex subsequently excludes PAPa from the Star-PAP target UTRs.
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30-uridylated, apparently destabilising the RNA [123,124,188,189].
In contrast, oligo (U)-tailing of human U6 snRNA has a stabilising
function [23,188]. In yeast, an additional type of 30-end tail has
been reported where the poly(A) tail is followed by a short U tract
that results in degradation of the mRNA [158]. PAPa forms poly(A)
tail at the 30-end, and Star-PAP makes both poly(A) tails (like
canonical PAPa) and also short terminal U tails (like a non-canon-
ical PAP) to distinct target RNAs. Given the enzymatic character of
Star-PAP and the number of target mRNAs it controls [20,23], there
could be yet another type of a heterogeneous 30-end tail having
both As and Us in the cell. Such tails would have entirely different
properties from that of either poly(A) or U tails [157,190].
6.2. Speciﬁcity for target mRNAs
It is clear that the two nuclear PAPs PAPa and Star-PAP control
distinct mRNA targets in the nucleus. However, it is unclear why
Star-PAP target mRNAs are speciﬁc to Star-PAP and not accessible
to PAPa, and vice versa. A possibility for the speciﬁcity is the
Star-PAP binding to its target pre-mRNA. Star-PAP footprint on
its targets HO-1 and BIK pre-mRNA indicated a GC-rich sequence
40–60 nucleotides upstream of the cleavage site [19,24] which
is present on all Star-PAP target mRNAs [19]. RNA-compete analy-
sis has also identiﬁed a speciﬁc Star-PAP (TUT1) binding oligonu-
cleotide (-AUA-) motif [191]. This motif is present within the
GC-rich sequence of Star-PAP footprints of all target mRNAs so
far studied [19,24], suggesting that this motif might provide selec-
tivity to Star-PAP for its target messages. However, this fails to
explain why PAPa cannot process Star-PAP target messages even
though intact canonical AAUAAA signal and cleavage site are pres-
ent. Sequence analysis has shown a U/GU deplete DSE in Star-PAPtarget pre-mRNAs, which is critical for CstF binding [19]. Therefore,
another possible explanation for PAPa exclusion from the Star-PAP
regulated transcripts could be the low U/GU sequence (suboptimal
DSE), which renders the pre-mRNA inaccessible to CstF, thus pre-
venting the recruitment of PAPa. However, some of the Star-PAP
target pre-mRNAs still possess DSE albeit weaker than the canon-
ical counterparts [24]. Therefore, yet another explanation is the
involvement of trans-acting factors that bind the pre-mRNA along
with Star-PAP and confer speciﬁcity to Star-PAP targets. Like Star-
PAP, other PAPs are also likely to have distinct sequence elements
at the 30-UTRs that determine the speciﬁcity of each PAP.
6.3. Signalling mediated regulation of polyadenylation
Star-PAP is regulated by signalling pathways through distinct
kinases. Like Star-PAP, PAPa too is regulated by phosphorylation;
however, the extracellular signal that triggers PAPa phopshory-
ation is unclear. Several serine and threonine residues within the
extended C-terminus of PAPa are phosphorylated by cdc2-cyclin
B [105,106]. During the mitotic phase of the cell cycle, this region
is hyperphosphorylated to inhibit PAP activity, which is then
reversed in the G1 phase [106]. Thus, this exempliﬁes a conditional
or temporal regulation of PAP by phosphorylation as per cellular
requirements. In addition, reports suggest that phosphorylation
of PAPa by ERK kinase promotes the PAP activity [192]. PAP phos-
phorylation could also modulate the interaction with other cleav-
age factors to regulate distinct cellular functions. Thus, regulation
of PAP could be an important mechanism for the cellular control
of gene expression.
On the other hand, Star-PAP activity and its target gene expres-
sions are stimulated by oxidative stress and nuclear PI4,5P2
[20,24]. The kinases and upstream signalling events modulating
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Star-PAP associates with Ser/Thr kinase casein kinase I (CKI)
[193,194], and protein kinase Cd (PKCd) [195–197]. Star-PAP is
phosphorylated at the proline rich region (PRR) in the catalytic
domain by CKI isoforms a and e, which is critical for Star-PAP
activity [152,153]. Knockdown of casein kinase or dephosphoryla-
tion of Star-PAP resulted in diminished Star-PAP activity. The PRR
contains several putative CKI phosphorylation sites, and is
likely to be phosphorylated at multiple sites. Both CKI isoforms
together regulate 30-processing of Star-PAP target HO-1 mRNA
[153]. Oxidative stress treatment resulted in the induction of
Star-PAP phosphorylation indicating the involvement of a stress
signalling pathway coupled with phosphorylation to regulate
Star-PAP.
Unlike the CKI isoforms, PKCd regulates Star-PAP activity down-
stream of DNA damage signalling [19]. PKCd interacts with and
phosphorylates Star-PAP. Interestingly, PKCd is required for the
DNA damage signal induced Star-PAP activity, but not for the oxi-
dative stress induced pathway. While CKI and the stress induced
pathway regulate genes involved in oxidative stress response such
as HO-1 and NQO-1, DNA damage and PKCd regulate the pro-
apoptotic gene BIK. This signiﬁes a signal mediated differential
regulation of Star-PAP target genes. Thus, modulation of PAP by
different signalling pathways regulates genes involved in distinct
cellular functions suggesting that PAPs act as regulatory molecules
that alter gene expression to mediate selective or conditional geneFig. 4. Model for signal mediated regulation of Star-PAP to differentially control the 30-e
integrate into the Star-PAP 30-end processing complex downstream of the signalling path
e) works downstream of oxidative stress to speciﬁcally regulate stress response genes HO
damage signal to regulate proapoptotic gene BIK through Star-PAP. The PKCd mediated p
acts as a central regulatory molecule at the 30-end of a gene that differentially controlsexpression. Differential regulation of Star-PAP by distinct signal-
ling pathways is depicted in Fig. 4.
6.4. Alternative polyadenylation
The requirements of distinct cis-elements at the 30-UTR of Star-
PAP target genes have been discussed above. All nuclear pre-mRNA
UTRs can have either Star-PAP speciﬁc or canonical PAP speciﬁc
cis-element (poly(A) site). Reports indicate that more than 50% of
mRNAs have multiple poly(A) sites at their 30-UTRs [76]. It is likely
that at least few of such mRNAs contain both Star-PAP and PAPa
speciﬁc cis-elements at the 30-UTR. This would result in alternate
selection of poly(A) sites by poly(A) polymerases. The regulation of
speciﬁc mRNAs or target 30-UTRs by distinct canonical PAP isoforms
has been reported in plants [117]. Several Star-PAP target genes
identiﬁed in the microarray analysis also harbour more than one
poly(A) site [20]. For example, NQO-1 has three poly(A) sites of
which mRNA encoded by the most distal site is induced by the toxin
dioxin.[198]. Knockdown of Star-PAP resulted in the loss of NQO-1
expression [20] suggesting that Star-PAP controls one or more
poly(A) sites of NQO-1. In addition, expressions of some Star-PAP
target genes are only partially diminished upon Star-PAP knockdown
[20]. Such genes could represent a set of APA regulated genes where
loss of Star-PAP regulated mRNA isoform is compensated by the
expression of alternate isoforms from PAPa controlled poly(A) site(s)
– a novel mechanism of APA site selection by PAPs.nd processing of distinct target messages. Various signal transduction components
way, to regulate different target genes. In this model, casein kinase (isoforms a and
-1 and NQO-1 through Star-PAP. On the other hand, PKCdworks in concert with DNA
athway is independent of oxidative stress regulation and vice versa. Thus, Star-PAP
the expression of target genes through various kinases and signalling molecules.
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It is evident that Star-PAP and PAPa assemble distinct 30-end
processing complexes. PAPa is not detected in the Star-PAP 30-
end processing complex and vice versa [20,24]. Intriguingly, there
has been growing evidence that 30-end processing factors are clo-
sely linked to the promoter, and at least in some cases may ride
with RNA Pol II complex to 30-end [199–204] (for review [205]).
Evidence suggests that 30-processing factor(s) such as CPSF are
delivered to the promoter by transcription factor TFIID and then
transferred to the elongating RNA pol II CTD [200,201]. Other stud-
ies also suggest the recruitment of 30-end processing factors such
as CPSF and CstF at the 50-end [206]. Consistently, in yeast cleavage
factors CFI and PFI have been detected with RNA Pol II starting at
the promoter [201]. Since 30-end processing factors exist in a tight
complex, it is likely that they may all be detected in association
with RNA Pol II either at the promoter, or after RNA Pol II clears
the promoter (for reviews [205,207,208]). Since PAPs directly
interact with CPSF [24,26], it is possible that PAPs associate with
RNAP-CPSF complex during transcription. However, at this point
there is no direct evidence that shows PAP association with RNA
Pol II. Nevertheless, ChIP experiments have shown that yeast
PAP1 is localised at the promoter, though it is preferentially bound
at the 30-UTR [209]. Thus, PAPs could join RNA Pol II via CPSF inter-
action during transcription elongation/initiation, or be recruited
speciﬁcally to the 30-end.
Both scenarios raise an important question: what determines
the choice between the two PAPs (Star-PAP and canonical PAPa)
to function at a particular 30-UTR? There are two possible models
for the PAP speciﬁcity at the 30-UTR: PAP selection, or 30-PAP
switch. In the PAP selection model speciﬁc cis-elements on the
30-UTR RNA select the required PAP. Alternatively, in the PAP
switch model the canonical PAPa predominantly associates with
30-RNA processing-transcription complex at the 30-UTR of all pre-
mRNAs. However, a PAP switch occurs at the 30-UTR of Star-PAPFig. 5. 30-PAP switch/PAP selection model. In this model, a PAP switch/selection at the 30
on the target UTR RNA.target mRNAs, to Star-PAP due to its speciﬁc binding to mRNA to
assemble a stable 30-processing complex. This model is shown in
Fig. 5. This mechanism of PAP selection/switch can be extrapolated
to other PAP isoforms as well. However, at present what factors
drive the PAP selection/switch remains to be determined.
8. Conclusion
In recent years, much progress has been made towards the
understanding of 30-end processing mechanisms mediated by the
two nuclear PAPs. Nevertheless, some key questions remain unad-
dressed, including the physiological signiﬁcance for such variations
in polyadenylation mechanisms. Indeed, the Star-PAP mediated
30-processing complex could offer an advantage of selective regula-
tion while employing canonical 30-processing factors [24]. Star-PAP
target genes such as HO-1 and NQO-1 are inducible stress response
genes stimulated during oxidative stress [210–212]. The particular
mechanism of Star-PAP dependent cleavage and its selective stim-
ulation by oxidative stress will help home in and induce stress
response genes while excluding global processing events that
should remain unaffected during oxidative stress. Thus, temporal
and/or speciﬁc stimulation of genes can occur through modulation
of distinct PAPs, under different signalling conditions.
Current data demonstrate that diverse PAP populations function
in the cell. Is the multiplicity of PAPs a cellular necessity or another
functional redundancy in the cell? The answer is unknown but
growing evidence suggests that the modulation of different PAPs
regulate distinct cellular functions. For example, Star-PAP and
PAPa are modulated by different kinases and signalling pathways
to control expression of distinct target messages. Not only different
PAPs but also distinct isoforms of canonical PAPa are differentially
expressed, and are likely to regulate genes conditionally, or in a tis-
sue dependent manner [12,17,18]. In conclusion, the existence of
differentially regulated diverse PAP populations immensely bene-
ﬁts the cellular machinery for gene regulation. Although research-end of a gene favouring a particular PAP is determined by the cis-elements present
2194 R.S. Laishram / FEBS Letters 588 (2014) 2185–2197over the last decade has considerably improved our knowledge on
PAP functions, further studies are required to unravel how distinct
PAPs attain speciﬁcity for their target transcripts and/or 30-UTR
selection.
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